| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Breast Imaging |
1 From the Ctr for Magnetic Resonance Research (S.M., P.J.B., E.H.B., M.G.), Dept of Radiology (S.M., P.J.B., E.H.B., L.I.E., M.T.N., T.H.E., M.G.), Cancer Ctr (R.L.B., D.Y., M.G.), Dept of Pathology/Laboratory Medicine (E.G.), Dept of Surgery (T.M.T.), and Dept of Medicine (D.Y.), Univ of Minnesota School of Medicine, 2021 Sixth St SE, Minneapolis, MN 55455. From the 2003 RSNA scientific assembly. Received Aug 19, 2003; revision requested Oct 31; revision received Jan 14, 2004; accepted Feb 16. Supported by DOD Breast Cancer Research Program DAMD 17–01-1–0331, NIH grants RR08079, CA92004, RR00400, and PHS Cancer Ctr Support Grant P30 CA77398, the Lillian Quist-Joyce Henline Chair in Biomedical Research, and the Tickle Family Land Grant Chair in Breast Cancer Research. Address correspondence to M.G. (e-mail: gar@cmrr.umn.edu).
PURPOSE: To determine if changes in the concentration of choline-containing compounds (tCho) from before primary systemic therapy (PST) to within 24 hours after the first treatment enable prediction of clinical response in patients with locally advanced breast cancer.
MATERIALS AND METHODS: Sixteen women with biopsy-confirmed locally advanced breast cancer scheduled to undergo doxorubicin-based PST were recruited. Magnetic resonance (MR) imaging and spectroscopy were performed at 4 T prior to treatment, within 24 hours after the first dose, and after the fourth dose. Lesion size was assessed by using gadolinium-enhanced MR imaging. Lesion tCho concentration was quantified by using single-voxel hydrogen 1 MR spectroscopy. Statistical analysis was performed by using the Pearson correlation coefficient and the Wilcoxon rank sum test.
RESULTS: Fourteen of 16 patients completed the protocol. In one patient, the level of tCho was not measurable because of unfavorable lesion morphology for MR spectroscopy voxel placement. Of the remaining 13 patients, four had inflammatory breast cancer, six had invasive ductal carcinoma, two had invasive lobular carcinoma, and one had mixed invasive ductal and lobular carcinoma. On the basis of the Response Evaluation Criteria in Solid Tumors, eight of 13 patients had an objective response and five had no response. The change in concentration of tCho from baseline to within 24 hours after the first dose of PST showed significant positive correlation with the change in lesion size (R = 0.79, P = .001). Change in tCho concentration within 24 hours after first dose was significantly different between patients with objective response and those with no response (P = .007).
CONCLUSION: These results suggest that the change in tCho concentration between baseline and 24 hours after the first dose of PST can serve as an indicator for predicting clinical response to doxorubicin-based chemotherapy in locally advanced breast cancer.
© RSNA, 2004
Index terms: Breast neoplasms, MR, 00.12145 • Breast neoplasms, therapy, 00.32 • Chemotherapy • Magnetic resonance (MR), spectroscopy
This article has been cited by other articles:
|
|
 |
|
  C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sachdev and D. Yee Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 39 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Kuhl, F. Traber, J. Gieseke, W. Drahanowsky, N. Morakkabati-Spitz, W. Willinek, M. von Falkenhausen, C. Manka, and H. H. Schild Whole-Body High-Field-Strength (3.0-T) MR Imaging in Clinical Practice * Part II. Technical Considerations and Clinical Applications Radiology, April 1, 2008; 247(1): 16 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Sah, R. Sharma, H. Kandpal, A. Seith, S. Rastogi, S. Bandhu, and N. R. Jagannathan In Vivo Proton Spectroscopy of Giant Cell Tumor of the Bone Am. J. Roentgenol., February 1, 2008; 190(2): W133 - W139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartella and W. Huang Proton (1H) MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S241 - S252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stanwell and C. Mountford In Vivo Proton MR Spectroscopy of the Breast RadioGraphics, October 1, 2007; 27(suppl_1): S253 - S266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hamstra, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Claudino, A. Quattrone, L. Biganzoli, M. Pestrin, I. Bertini, and A. Di Leo Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications J. Clin. Oncol., July 1, 2007; 25(19): 2840 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Jacobs, T. S. Ibrahim, and R. Ouwerkerk AAPM/RSNA Physics Tutorials AAPM/RSNA Physics Tutorials for Residents: MR Imaging: Brief Overview and Emerging Applications RadioGraphics, July 1, 2007; 27(4): 1213 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy PNAS, March 6, 2007; 104(10): 4014 - 4019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sachdev and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shi, P. Schraedley-Desmond, S. Napel, E. W. Olcott, R. B. Jeffrey Jr, J. Yee, M. E. Zalis, D. Margolis, D. S. Paik, A. J. Sherbondy, et al. CT Colonography: Influence of 3D Viewing and Polyp Candidate Features on Interpretation with Computer-aided Detection. Radiology, June 1, 2006; 239(3): 768 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Kuhl, P. Jost, N. Morakkabati, O. Zivanovic, H. H. Schild, and J. Gieseke Contrast-enhanced MR Imaging of the Breast at 3.0 and 1.5 T in the Same Patients: Initial Experience Radiology, June 1, 2006; 239(3): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bartella, E. A. Morris, D. D. Dershaw, L. Liberman, S. B. Thakur, C. Moskowitz, J. Guido, and W. Huang Proton MR Spectroscopy with Choline Peak as Malignancy Marker Improves Positive Predictive Value for Breast Cancer Diagnosis: Preliminary Study Radiology, June 1, 2006; 239(3): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Sullivan The Role of Molecular Imaging in Development of Novel Therapies Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 133 - 135. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Evelhoch, M. Garwood, D. Vigneron, M. Knopp, D. Sullivan, A. Menkens, L. Clarke, and G. Liu Expanding the Use of Magnetic Resonance in the Assessment of Tumor Response to Therapy: Workshop Report Cancer Res., August 15, 2005; 65(16): 7041 - 7044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. McPhail, Y.-L. Chung, B. Madhu, S. Clark, J. R. Griffiths, L. R. Kelland, and S. P. Robinson Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy Clin. Cancer Res., May 15, 2005; 11(10): 3705 - 3713. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
